Quantcast
Home > Quotes > OTLKW

Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) Quote & Summary Data

OTLKW 
$0.27
*  
0.0224
7.66%
Get OTLKW Alerts
*Delayed - data as of May 24, 2019  -  Find a broker to begin trading OTLKW now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    OTLKW After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 0.20 / $ 0.27
1 Year Target
Today's High / Low
$ 0.30 / $ 0.23
Share Volume
29,727
50 Day Avg. Daily Volume
N/A
Previous Close
$ 0.2924
52 Week High / Low
$ 0.79 / $ 0.0114
Market Cap
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
29,727
50 Day Avg. Daily Volume:
N/A

Trading Range

The current last sale of $0.27 is 2,268.42% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 0.30 $ 0.79
 Low: $ 0.23 $ 0.0114

Company Description (as filed with the SEC)

We are a late clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a complex, technically challenging and commercially attractive monoclonal antibody, or mAb, for various ophthalmic indications. Our goal is to launch ONS-5010 as the first, and only, approved bevacizumab in the United States, Europe, Japan and other markets for the treatment of wet age related macular degeneration, or wet AMD, diabetic macular edema, or DME, and branch retinal vein occlusion, or BRVO. ONS-5010 is an innovative mAb therapeutic product candidate currently enrolling patients in a clinical trial outside the United States designed to serve as the first of two adequate and well controlled studies evaluating ONS-5010 as a treatment for wet AMD. We plan to submit an investigational new drug, or IND, application with the U.S. Food and Drug Administration, or FDA, in the first quarter of calendar 2019. The U.S.  ... More ...  

Nasdaq Official Price

Open Price:
$ 0.2796
Open Date:
May 24, 2019
Close Price:
$ 0.27
Close Date:
May 24, 2019


Research Brokers before you trade

Want to trade FX?

Analyst Info